These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9377091)

  • 1. The discovery, characterization and crystallographically determined binding mode of an FMOC-containing inhibitor of HIV-1 protease.
    Rutenber EE; De Voss JJ; Hoffman L; Stroud RM; Lee KH; Alvarez J; McPhee F; Craik C; Ortiz de Montellano PR
    Bioorg Med Chem; 1997 Jul; 5(7):1311-20. PubMed ID: 9377091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine.
    Baldwin ET; Bhat TN; Gulnik S; Liu B; Topol IA; Kiso Y; Mimoto T; Mitsuya H; Erickson JW
    Structure; 1995 Jun; 3(6):581-90. PubMed ID: 8590019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.
    Lindberg J; Pyring D; Löwgren S; Rosenquist A; Zuccarello G; Kvarnström I; Zhang H; Vrang L; Classon B; Hallberg A; Samuelsson B; Unge T
    Eur J Biochem; 2004 Nov; 271(22):4594-602. PubMed ID: 15560801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probing the S1/S1' substrate binding pocket geometry of HIV-1 protease with modified aspartic acid analogues.
    Short GF; Laikhter AL; Lodder M; Shayo Y; Arslan T; Hecht SM
    Biochemistry; 2000 Aug; 39(30):8768-81. PubMed ID: 10913288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-hydroxy-5,6-dihydro-2H-pyran-2-ones.3. Bicyclic and hetero-aromatic ring systems as 3-position scaffolds to bind to S1' and S2' of the HIV-1 protease enzyme.
    Ellsworth EL; Domagala J; Prasad JV; Hagen S; Ferguson D; Holler T; Hupe D; Graham N; Nouhan C; Tummino PJ; Zeikus G; Lunney EA
    Bioorg Med Chem Lett; 1999 Jul; 9(14):2019-24. PubMed ID: 10450973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. X-ray structure of HIV-1 protease tethered dimer complexed to ritonavir.
    Das A; Rao DR; Hosur MV
    Protein Pept Lett; 2007; 14(6):565-8. PubMed ID: 17627597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases.
    Chen Z; Li Y; Chen E; Hall DL; Darke PL; Culberson C; Shafer JA; Kuo LC
    J Biol Chem; 1994 Oct; 269(42):26344-8. PubMed ID: 7929352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interdependence of Inhibitor Recognition in HIV-1 Protease.
    Paulsen JL; Leidner F; Ragland DA; Kurt Yilmaz N; Schiffer CA
    J Chem Theory Comput; 2017 May; 13(5):2300-2309. PubMed ID: 28358514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.
    Bäckbro K; Löwgren S; Osterlund K; Atepo J; Unge T; Hultén J; Bonham NM; Schaal W; Karlén A; Hallberg A
    J Med Chem; 1997 Mar; 40(6):898-902. PubMed ID: 9083478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights from atomic-resolution X-ray structures of chemically synthesized HIV-1 protease in complex with inhibitors.
    Johnson EC; Malito E; Shen Y; Pentelute B; Rich D; Florián J; Tang WJ; Kent SB
    J Mol Biol; 2007 Oct; 373(3):573-86. PubMed ID: 17869270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitor binding at the protein interface in crystals of a HIV-1 protease complex.
    Brynda J; Rezácová P; Fábry M; Horejsí M; Stouracová R; Soucek M; Hradílek M; Konvalinka J; Sedlácek J
    Acta Crystallogr D Biol Crystallogr; 2004 Nov; 60(Pt 11):1943-8. PubMed ID: 15502300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonpeptidic potent HIV-1 protease inhibitors: (4-hydroxy-6-phenyl-2-oxo-2H- pyran-3-yl)thiomethanes that span P1-P2' subsites in a unique mode of active site binding.
    Prasad JV; Para KS; Tummino PJ; Ferguson D; McQuade TJ; Lunney EA; Rapundalo ST; Batley BL; Hingorani G; Domagala JM
    J Med Chem; 1995 Mar; 38(6):898-905. PubMed ID: 7699705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of P1-P3 groups in symmetric and asymmetric HIV-1 protease inhibitors.
    Andersson HO; Fridborg K; Löwgren S; Alterman M; Mühlman A; Björsne M; Garg N; Kvarnström I; Schaal W; Classon B; Karlén A; Danielsson UH; Ahlsén G; Nillroth U; Vrang L; Oberg B; Samuelsson B; Hallberg A; Unge T
    Eur J Biochem; 2003 Apr; 270(8):1746-58. PubMed ID: 12694187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity.
    Logsdon BC; Vickrey JF; Martin P; Proteasa G; Koepke JI; Terlecky SR; Wawrzak Z; Winters MA; Merigan TC; Kovari LC
    J Virol; 2004 Mar; 78(6):3123-32. PubMed ID: 14990731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance.
    Hong L; Zhang XC; Hartsuck JA; Tang J
    Protein Sci; 2000 Oct; 9(10):1898-904. PubMed ID: 11106162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysine derivatives as potent HIV protease inhibitors. Discovery, synthesis and structure-activity relationship studies.
    Bouzide A; Sauvé G; Yelle J
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1509-13. PubMed ID: 15713418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure of HOE/BAY 793 complexed to human immunodeficiency virus (HIV-1) protease in two different crystal forms--structure/function relationship and influence of crystal packing.
    Lange-Savage G; Berchtold H; Liesum A; Budt KH; Peyman A; Knolle J; Sedlacek J; Fabry M; Hilgenfeld R
    Eur J Biochem; 1997 Sep; 248(2):313-22. PubMed ID: 9346283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site.
    Mahalingam B; Wang YF; Boross PI; Tozser J; Louis JM; Harrison RW; Weber IT
    Eur J Biochem; 2004 Apr; 271(8):1516-24. PubMed ID: 15066177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active site binding modes of curcumin in HIV-1 protease and integrase.
    Vajragupta O; Boonchoong P; Morris GM; Olson AJ
    Bioorg Med Chem Lett; 2005 Jul; 15(14):3364-8. PubMed ID: 15950462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition and substrate recognition--a computational approach applied to HIV protease.
    Vinkers HM; de Jonge MR; Daeyaert ED; Heeres J; Koymans LM; van Lenthe JH; Lewi PJ; Timmerman H; Janssen PA
    J Comput Aided Mol Des; 2003 Sep; 17(9):567-81. PubMed ID: 14713189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.